ALPMF News and Press, Astellas Pharma Inc From 12/01/23

2023-12-01 09:18:27 ET More on Apellis Pharmaceuticals Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Apellis Pharmaceuticals: Looking For Entry Around Crucial Q3 Earn...

2023-11-19 21:37:59 ET Summary Soros Fund Management's 13F portfolio value increased by 10% to $7.05B, with 209 positions. Top three individual stocks held were Horizon Therapeutics, Activision Blizzard, and Alphabet. New stakes included Activision Blizzard, Abcam plc, Novo No...

2023-11-07 19:06:24 ET Summary A phase 2 study is being advanced using EPI-7386 in combination with enzalutamide to treat patients with metastatic castration-resistant prostate cancer; Positive updated PSA data presented at medical conference. EPI-7386 is being advanced as a monot...

2023-11-05 12:17:29 ET Summary The UST yield curve has steepened and this could provide an opportunity to buy US banking stocks on weakness in a no-recession scenario. Japan and Eurozone exporters can benefit from a global downturn due to easier central bank policies depreciating ...

2023-10-27 16:13:47 ET Summary Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved for multiple GI indications. Ironwood recently a...

2023-10-23 14:25:26 ET More on Seattle Genetics Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors Seagen ticks higher as EU approves $43B sale to Pfizer Pfizer likely turned over all documents to FTC for Seagen acquistion - r...

2023-10-13 09:38:00 ET More on Astellas Pharma ADR Astellas: Earnings Power, Asset Factors Attractive, Reiterate Hold On Valuation Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript Merck succeeds in Phase 3 trial for bladder cancer therapy Apellis...

2023-10-05 07:30:43 ET More on Merck Merck Vs. GSK: The Game-Changer Race In Pharma Excellence Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects Merck: A Blue-Chip Dividend Stock Worth Buying US government to stop distributing Merck's CO...

2023-09-27 08:59:28 ET Summary Poseida Therapeutics exhibits robust financials with Q2 2023 collaboration revenue surging to $20.01M and a recent $50M Astellas investment extending its cash runway. Despite stock underperformance, Poseida's diversified CAR-T pipeline shows momentum...

2023-09-22 06:49:12 ET More on Merck Seeking Alpha’s Quant Rating on Merck Historical earnings data for Merck Financial information for Merck Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects Merck: A Blue-Chip Dividend St...